Verrica Pharmaceuticals 3Q26 Earnings Conference Call - VERRICA PHARMACEUTICALS INC

Financial Performance:

• Total revenue for Q3 2026 was $6.9 million, a decrease from $14.3 million in Q3 2025 which included a one-time $10 million milestone payment from Torrey; underlying U.S. net product revenue was $5.7 million (up 11.9% QoQ and 57.9% YoY).
• U.S. net Y-CANTH product revenue grew to $5.7 million, driven by increased deliveries and improved yield per prescription; licensing revenue was $1.2 million (mainly Torrey supply) versus $10.7 million in the prior year.
• Gross product margins improved to 89.8% from 79.1% in the prior year; R&D expenses rose to $7.6 million (excluding SBC) primarily due to $3.7 million in costs for the Common Warts Phase III program.
• Net loss on a GAAP basis was $12.4 million ($0.58/share); non-GAAP net loss was $10.5 million ($0.49/share).
• Cash position was $14.4 million as of September 30, 2026; the company has unlocked an additional $15 million credit facility, extending its cash runway to potentially Q4 2027 assuming full utilization.

Guidance and Future Outlook:

• Management expects top-line data from the COVE-2 pivotal trial (Common Warts) in Q1 2027 and from COVE-3 in mid-2027; regulatory submission for Common Warts is targeted as quickly as possible post-readout.
• Q4 2026 revenue guidance reflects expected seasonality with lower volumes due to summer travel patterns and consumer behavior, though long-term growth drivers remain focused on adoption and yield improvement.
• Strategic goal is to launch Y-CANTH into the Common Warts market, projected to be a multi-billion dollar opportunity, leveraging existing commercial infrastructure and prescriber overlap.
• Future plans include finalizing protocols for a Gorlin syndrome Proof-of-Concept (POC) study to complement the sporadic BCC Phase III program, with potential label expansion strategies under development.

Business Segments and Product Lines:

• Y-CANTH (Molluscum): Record revenue driven by expanding distribution in specialty and retail pharmacies; dispensed units totaled 19,135 (up 35.8% YoY); commercial efforts now focus on reducing prescription leakage and shifting "watch-and-wait" prescribers to adopters.
• Common Warts Program: Completed enrollment in COVE-2 trial; enrolled >50% of target in COVE-3 trial ahead of schedule; program supported by $40 million from partner Torrey Pharmaceutical covering ~90% of trial costs.
• VP315 (Basal Cell Carcinoma): Exploring a POC study in Gorlin syndrome based on promising Phase II data showing 97% objective response and potential abscopal effects; FDA alignment obtained to include Gorlin patients in future development.
• International: Exclusive agreement with Madomi Pharma for commercialization in Israel; collaboration with Torrey for Japan launch (commercial supply transitioning to royalty basis).

Market and Competitive Landscape:

• Molluscum: Primary competitive challenge is the entrenched "watch-and-wait" mindset; new pooled data showing 4x faster clearance and 3x higher complete clearance rates aims to shift clinical practice toward early intervention.
• Common Warts: Market size estimated at 22 million in the U.S. with zero FDA-approved prescription therapies; current standard of care involves painful, scarring surgical procedures.
• Gorlin Syndrome/BCC: No FDA-approved therapies exist; current oral hedgehog inhibitors suffer from tolerability issues (muscle cramps, taste loss); VP315 offers a novel lytic/immunologic approach distinct from pathway inhibitors.
• Distribution: Managing a 50/50 split between medical and pharmacy benefits; key strategy involves redirecting medical benefit claims to in-network pharmacies to improve yield.

Risks and Challenges:

• Seasonality: Q3 and Q4 volumes are impacted by summer travel seasonality affecting both patient and provider activity.
• Clinical Execution: Reliance on achieving positive pivotal data for Common Warts to unlock the multi-billion dollar market opportunity.
• Reimbursement: Continued need to optimize coverage and navigate payer restrictions, particularly for medical benefit claims.
• Competition: The "watch-and-wait" behavior remains a significant hurdle for Y-CANTH adoption in the molluscum market.
• Development Risk: Uncertainty surrounding the translation of sporadic BCC data to the Gorlin syndrome population and the timeline for final Phase III protocol design.

Management Commentary and Tone:

• Tone was confident and optimistic, highlighting record revenue, successful enrollment milestones, and the unlocking of additional capital.
• Management emphasized the "compelling future" driven by the Y-CANTH franchise, the potential Common Warts label expansion, and the differentiated pipeline asset VP315.
• CEO Jason Rieger and CFO John Kirby expressed strong conviction in the commercial strategy's ability to convert "dabblers" to loyalists and optimize reimbursement yield.
• CMO Noah Rosenberg highlighted the unmet need in Gorlin syndrome and the potential for VP315 to transform the treatment paradigm.

Analyst Questions and Answers:

• Growth Drivers (Stacy Q, TD Cowan): Growth attributed to prescriber adoption shifts, yield optimization via pharmacy channel management, and continued education on clinical superiority over "watch-and-wait." Q4 expected to reflect normal seasonality with lower volumes.
• Gorlin Study Design (Stacy Q): Confirmation of a Proof-of-Concept study in Gorlin patients to validate efficacy and explore abscopal effects before finalizing the Phase III strategy; data will inform whether to pursue a specific Gorlin Phase III or integrate data into the sporadic BCC program.
• Interim Analysis (Dennis Ding, Jefferies): Clarified that the interim analysis was a "promising zone" analysis (blinded) indicating no further enrollment was needed; no specific futility analysis was conducted.
• Standard of Care (Dennis Ding): No approved therapies for common warts exist; the efficacy hurdle is a clinically meaningful improvement in clearance over vehicle, not a specific numerical threshold against a non-existent competitor.
• Non-U.S. Revenue (Ram Selvaraju): Torrey collaboration revenue will likely decrease sequentially as Torrey transitions to self-manufacturing in Japan, shifting to a royalty-based model; no immediate stocking impact expected to distort future trends.
• Competitive Landscape (Ram Selvaraju): VP315 is viewed as potentially synergistic with oral hedgehog inhibitors; VP315 treats existing lesions (lytic), while others aim to prevent new lesions (preventive).
• Yield vs. Volume (Serge Belanger, Needham): Revenue growth despite unit volume dip was due to improved gross-to-net yield and redirecting medical claims to pharmacy channels; this is a structural improvement expected to continue.
• Phase 3 Timing (Thomas Flaten, Lake Street): A separate POC in Gorlin is being pursued to gather critical data before committing to a blinded Phase III in that population; regulatory submission for Common Warts will be aggressive but depends on data release.

Other Key Points:

• The company successfully met operational and revenue milestones to unlock the remaining $15 million of its $27.5 million credit facility, funded by chairman Paul Manning.
• VP315 Phase II data showed an average 86% reduction in treated lesion size and a 67% reduction in untreated (abscopal) lesions, supporting the mechanism of action for the proposed Gorlin study.
• Management reiterated the "multi-billion dollar" potential of expanding Y-CANTH to Common Warts, citing the lack of current treatments and high clinician overlap.
• The company remains committed to patient access initiatives, including co-pay assistance programs to mitigate financial barriers for commercially insured patients.